Market News & Trends
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer
BriaCell Therapeutics Corp. recently announced its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the…
MAIA Biotechnology Granted Patent for Next-Generation Telomere-Targeting Agents for Cancer Therapy
MAIA Biotechnology, Inc. recently announced the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer…
NodThera Demonstrates Reversal of Neuroinflammation & Inflammation in Parkinson’s Disease With Oral NLRP3 Inhibitor
NodThera recently announced the full publication of positive data from its Parkinson’s disease Phase 1b/2a study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3…
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
AAVantgarde Bio recently announced the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic…
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for Registrational Trial of AXPAXLI in NPDR
Ocular Therapeutix, Inc. recently announced it has received written agreement regarding a registrational trial design from the US FDA under a Special Protocol Assessment (SPA)…
Enable Injections Announces enFuse System Regulatory Approval & MRHA Medical Device Registration
Enable Injections, Inc. recently announced the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ANVISA) approved the enFuse system for administration of medication…
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination & Effective Maintenance Following Discontinuation of GLP-1RA Therapy
Aardvark Therapeutics, Inc. recently announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in…
Branded Legacy Finalizes Transformative Acquisition of Bio Legacy Evaluative Group, Unlocking Explosive Growth Potential in Biotech & Drug Delivery
Branded Legacy, Inc. recently announced the completion of its game-changing acquisition of Bio Legacy Evaluative Group, formerly Menlo Health (Bio Legacy). This strategic move, executed…
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances With a Potential to Realize the Full Promise of KRAS & PI3K Inhibition
BridgeBio Oncology Therapeutics, Inc. (BBOT) recently announced the closing of its previously announced business combination with Helix Acquisition Corp. II (formerly Nasdaq: HLXB) (Helix), a…
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
XOMA Royalty Corporation recently announced it has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ: TSBX)…
FDA Approves Tiziana Life Sciences' Phase 2 IND for Multiple System Atrophy
Tiziana Life Sciences, Ltd. recently announce the US FDA has approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with…
Sever Pharma Solutions Expands Partnership With Silo Pharma on Novel Ketamine-Based Implant for Chronic Pain & Fibromyalgia
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled-release systems for high potent drugs, recently announced an expanded agreement with…
FoRx Therapeutics Initiates First-in-Human Trial With Novel Anti-Cancer Drug Targeting DNA Damage Response
FoRx Therapeutics recently announced the dosing of the first patient in a first-in-human clinical study of FORX-428, a novel PARG inhibitor designed to target and…
GT Biopharma Advances Into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma, Inc. recently announced initiation of dosing in Cohort 3 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or…
Legend Biotech Reports Recent Highlights & Second Quarter Results
Legend Biotech Corporation recently reported its second quarter 2025 unaudited financial results and key corporate highlights. “The groundbreaking 5-year survival data from CARTITUDE-1, with one-third…
Nanexa Signs Continuation of Feasibility Agreement With Major Pharmaceutical Company to Investigate PharmaShell Long-Acting Formulations in a Multi-Billion US Market
Nanexa has recently announced the signing of an extension of a feasibility agreement with a major pharmaceutical company to investigate the use of Nanexa´s proprietary…
Assembly Biosciences Reports Positive Interim Results From Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate Showing Reductions in Viral Shedding Rate & Genital Lesion Rate in Recurrent Genital Herpes
Assembly Biosciences, Inc. recently announced positive interim antiviral activity, clinical outcomes, safety, and pharmacokinetic (PK) results from a Phase 1b study evaluating ABI-5366, an investigational…
Genmab Announces Phase 3 Trial Met Dual Primary Endpoints in Patients With Relapsed/Refractory Follicular Lymphoma
Genmab A/S recently announced positive results of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combination with rituximab andlenalidomide (R2) versus…
Almirall & Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Almirall and Absci Corporation recently announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall’s selection of a second target aimed at dermatological indications.…
Parkinson’s Disease Market to Grow to $7 Billion by 2033
The Parkinson’s disease (PD) market across the seven major markets (7MM) is forecast to grow at a compound annual growth rate (CAGR) of 7.6% from…
